Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Recruiting · NCT04844866 · Registry updated 2026-06-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, diffuse large B-cell lymphoma, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-06-10 | NCT04844866 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| ICON plc | 21 |
| Miltenyi Biomedicine GmbH | 22 |
51 results · Page 1 of 3
Research sites
Swipe the table sideways for more columns.